Literature DB >> 28500695

Clinical characteristics and survival of systemic sclerosis patients with pulmonary hypertension and elevated wedge pressure: Observations from the PHAROS cohort.

Matthew R Lammi1, Lesley A Saketkoo2, Jessica K Gordon3, Paula Lauto1, Karen Fagan4, Virginia D Steen5.   

Abstract

BACKGROUND AND
OBJECTIVE: Systemic sclerosis (SSc) is a complex autoimmune disease commonly associated with pulmonary hypertension (PH). When associated with elevated pulmonary artery wedge pressure (PAWP), pulmonary artery pressure (PAP) is either in-proportion (post-capillary PH) or higher than expected (combined PH) relative to the increased PAWP.
METHODS: Patients from the PHAROS registry (a prospective observational cohort of SSc-PH patients) who had mean PAP ≥ 25 and PAWP > 15 on right heart catheterization were stratified based on diastolic pressure gradient (DPG). Kaplan-Meier analysis was performed to compare survival and PH-related hospitalization. Baseline factors were compared between patients dying and those who survived using Cox regression analysis.
RESULTS: A total of 59 patients were included, of whom 21 (36%) patients were classified as combined PH and 38 (64%) had post-capillary PH. No baseline characteristics were significantly different between the two groups. There were no differences in survival or PH-related hospitalization between the groups. The only baseline factor independently associated with death was lower 6-min walk distance (6MWD) (hazard ratio (HR): 1.33 per 25 m decrease, 95% CI: 1.11-1.59, P = 0.002). PH-specific medications were started during follow-up in significantly more patients in the combined PH group compared with the post-capillary group (86% vs 50%, P = 0.01).
CONCLUSION: Outcomes were similar between SSc patients with post-capillary PH and combined pre- and post-capillary PH. 6MWD at baseline can predict risk for death in SSc patients with PH and an elevated PAWP. More patients with combined PH were started on PH-specific medications, and the clinical benefit of treating this subgroup specifically in SSc patients needs further exploration.
© 2017 Asian Pacific Society of Respirology.

Entities:  

Keywords:  diastolic dysfunction; pulmonary hypertension; scleroderma; systemic sclerosis; treatment

Mesh:

Year:  2017        PMID: 28500695      PMCID: PMC5597455          DOI: 10.1111/resp.13067

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  28 in total

1.  Six-minute walk distance as a marker for disability and complaints in patients with systemic sclerosis.

Authors:  Katrin Deuschle; Katharina Weinert; Mike O Becker; Marina Backhaus; Dörte Huscher; Gabriela Riemekasten
Journal:  Clin Exp Rheumatol       Date:  2011-05-13       Impact factor: 4.473

2.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.

Authors:  S Miyamoto; N Nagaya; T Satoh; S Kyotani; F Sakamaki; M Fujita; N Nakanishi; K Miyatake
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

3.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.

Authors:  Milton Packer; John McMurray; Barry M Massie; Abraham Caspi; Vincent Charlon; Alain Cohen-Solal; Wolfgang Kiowski; William Kostuk; Henry Krum; Barry Levine; Paolo Rizzon; Jordi Soler; Karl Swedberg; Susan Anderson; David L Demets
Journal:  J Card Fail       Date:  2005-02       Impact factor: 5.712

4.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

5.  Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in "out-of-proportion" pulmonary hypertension.

Authors:  Christian Gerges; Mario Gerges; Marie B Lang; Yuhui Zhang; Johannes Jakowitsch; Peter Probst; Gerald Maurer; Irene M Lang
Journal:  Chest       Date:  2013-03       Impact factor: 9.410

6.  Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis.

Authors:  Y Allanore; C Meune; M C Vonk; P Airo; E Hachulla; P Caramaschi; G Riemekasten; F Cozzi; L Beretta; C T Derk; A Komócsi; D Farge; A Balbir; V Riccieri; O Distler; A Chialà; N Del Papa; K Pasalic Simic; M Ghio; B Stamenkovic; S Rednic; N Host; R Pellerito; E Zegers; A Kahan; U A Walker; M Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

7.  Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.

Authors:  Inder Anand; John McMurray; Jay N Cohn; Marvin A Konstam; Thomas Notter; Kurt Quitzau; Frank Ruschitzka; Thomas F Lüscher
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

8.  A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Sébastien Sanges; David Launay; Rennie L Rhee; Olivier Sitbon; Éric Hachulla; Luc Mouthon; Loïc Guillevin; Laurence Rottat; David Montani; Pascal De Groote; Vincent Cottin; Pascal Magro; Grégoire Prévot; Fabrice Bauer; Emmanuel Bergot; Céline Chabanne; Martine Reynaud-Gaubert; Sylvie Leroy; Matthieu Canuet; Olivier Sanchez; Christophe Gut-Gobert; Claire Dauphin; Christophe Pison; Clément Boissin; Gilbert Habib; Pierre Clerson; François Conesa; Jean-François Cordier; Steven M Kawut; Gerald Simonneau; Marc Humbert
Journal:  Ann Rheum Dis       Date:  2015-08-31       Impact factor: 19.103

9.  Five-year follow-up of left ventricular diastolic function in systemic sclerosis patients: determinants of mortality and disease progression.

Authors:  Réka Faludi; Gyöngyvér Költő; Barbara Bartos; Georgina Csima; László Czirják; András Komócsi
Journal:  Semin Arthritis Rheum       Date:  2014-04-13       Impact factor: 5.532

10.  Systolic and diastolic function in patients with systemic sclerosis.

Authors:  Laura Poanta; Razvan Dadu; Cristina Tiboc; Simona Rednic; Dan Dumitrascu
Journal:  Eur J Intern Med       Date:  2008-11-29       Impact factor: 4.487

View more
  3 in total

1.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

2.  Diversity of hemodynamic types in connective tissue disease associated pulmonary hypertension: more than a subgroup of pulmonary arterial hypertension.

Authors:  Xingbei Dong; Yue Shi; Ying Xia; Xiao Zhang; Junyan Qian; Jiuliang Zhao; Jinmin Peng; Qian Wang; Li Weng; Mengtao Li; Bin Du; Xiaofeng Zeng
Journal:  BMC Pulm Med       Date:  2022-08-01       Impact factor: 3.320

Review 3.  An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients.

Authors:  Barbara Ruaro; Francesco Salton; Elisa Baratella; Paola Confalonieri; Pietro Geri; Riccardo Pozzan; Chiara Torregiani; Roberta Bulla; Marco Confalonieri; Marco Matucci-Cerinic; Michael Hughes
Journal:  Diagnostics (Basel)       Date:  2022-03-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.